Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate

With more than 30 years’ experience in pharma and biotech, Clive Dix has seen the industry evolve and take on many challenges. He spoke to Scrip about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.

vaccine up close
• Source: Alamy

Clive Dix is used to sorting out complicated challenges. He has founded and run several biotechs in his time and has a broad knowledge of the scientific and commercial landscapes of a variety of therapeutic areas. But he really found himself in the eye of the storm when in 2020 he was appointed deputy chair of the UK’s Vaccine Taskforce to help lead efforts to find and manufacture a coronavirus vaccine. The UK government established the Taskforce in March 2020, and it reported directly to the Business Secretary. Dame Kate Bingham was appointed the Taskforce’s chair in May 2020, and Dix later stepped up to lead as interim chair for a period in early 2021 after she stood down.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Scrip

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies